Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
RGLS > SEC Filings for RGLS > Form 8-K on 10-Jun-2013All Recent SEC Filings

Show all filings for REGULUS THERAPEUTICS INC. | Request a Trial to NEW EDGAR Online Pro

Form 8-K for REGULUS THERAPEUTICS INC.


10-Jun-2013

Entry into a Material Definitive Agreement


Item 1.01 Entry into a Material Definitive Agreement.

On June 6, 2013, Regulus Therapeutics Inc. (the "Company") entered into an Amendment ("Amendment") to the Product Development and Commercialization Agreement with Glaxo Group Limited ("GSK") dated April 17, 2008, as amended in February 2010, June 2010, July 2011 and June 2012 (as amended, the "Agreement"). Under the terms of the Amendment, the parties have agreed that a specific compound targeting miR-122 for the treatment of the Hepatitis C Virus (the "Compound") will no longer be a collaboration compound under the Agreement, thereby permitting the Company to develop and commercialize the Compound outside of the Agreement. GSK will have no further option with respect to the Compound or any further milestone or royalty obligations related to the Compound, and the Company will have no reverse royalty obligation to GSK with respect to the Compound. The exclusivity provisions of the Agreement will also no longer apply to the Compound, such that the Company or any future sublicensee of the Compound will not be restricted by the Agreement from developing, manufacturing or commercializing the Compound. In addition, except to a limited extent provided for in the Amendment, the Company will have no obligation to perform any research or development activities under the parties' miR-122 program unless mutually agreed upon by the parties. The Amendment does not otherwise affect GSK's rights with respect to the miR-122 program under the Agreement. The foregoing description of the Amendment is qualified in its entirety by reference to the Amendment, a copy of which will be filed as an exhibit to the Company's next Quarterly Report on Form 10-Q.


  Add RGLS to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for RGLS - All Recent SEC Filings
Sign Up for a Free Trial to the NEW EDGAR Online Pro
Detailed SEC, Financial, Ownership and Offering Data on over 12,000 U.S. Public Companies.
Actionable and easy-to-use with searching, alerting, downloading and more.
Request a Trial      Sign Up Now


Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.